China Medical System Holdings Limited(AIM:CMSH) is pleased to announce that CMS Public Research Center for Polypeptide Innovative Drugs was approved by National Development and Reform Commision in August 2008， and has been listed in Special Construction Projects for Public Service of National Biological Industry Base， CMS was one of the two companies which were listed in the project this time in Shenzhen.
CMS Public Research Center for Polypeptide Innovative Drugs is planned to contain pharmacodynamics research platform， polypeptide and small molecular drug synthesis platform， new dosage form research platform， pharmacokinetics research platform， and drug quality research platform.The Research Center covers an area of 4800 square meters with a total investment budget of RMB60，750，000. By then CMS would get financial support from national government for about RMB8，000，000 and from Shenzhen government for about RMB2，000，000.
Once the Research Center is put into service， it will provide with large-scale and sophisticated equipments for Shenzhen National Biological Industry Base and related biological companies as well as other research institutions in polypeptide research field to promote the share for innovation resources， efficiently decrease the research costs and risks and finally promote the industrialization of innovative polypeptide drugs.